Posts

Real-World evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex

/by

Highly purified cannabidiol (CBD) has a broad spectrum of action and could be useful for the treatment of drug resistant epilepsy regardless of etiology or syndrome. Multicenter retrospective study that evaluated the efficacy and safety of CBD for the treatment of drug resistant epilepsy of different etiologies in patients >2 years of age.

Read more

Use of cannabinol in the treatment of epilepsy: Lennox-Gastaut Syndrome , Dravet, and Tuberous Sclerosis Complex

/by

Purpose: The objective of this systematic review with meta-analysis was to evaluate the efficiency, safety and short and long term tolerability of Cannabidiol CBD, as an adjunct treatment , in children and adults with Dravet Syndrome (SD) and Lennox Gastaut Syndrome(LGS) or Tuberous Sclerosis Complex with inadequate control of seizures.

Read more

Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial

/by

Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were invited to enroll in this long-term open-label extension (OLE) trial, GWPCARE5 (NCT02224573). We present the final analysis of safety and efficacy outcomes from GWPCARE5.

Read more

Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial

/by

Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were invited to enroll in this long-term open-label extension (OLE) trial, GWPCARE5 (NCT02224573). We present the final analysis of safety and efficacy outcomes from GWPCARE5.

Read more

Cannabidiol in conjunction with clobazam: analysis of four randomized‐controlled trials

/by

Authors: Boudewijn Gunning, Maria Mazurkiewicz‐Beldzinska, Richard F.M. Chin, Hari Bhathal Charlotte Nortvedt, Eduardo Dunayevich, Daniel Checketts Published in Acta Neurologica Scandinavica September 2020 Abstract Objectives To assess the efficacy and…

Read more

Cannabinoids in treatment-resistant epilepsy: A review.

/by

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017
—
Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

Read more

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

/by

Authors: Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, et al
The Lancet Neurology, March 2016
—
BACKGROUND: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish w…

Read more

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

/by

Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014
—
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…

Read more